The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 344:87-94 January 11, 2001 Number 2
NextNext

Adverse Events, Including Death, Associated with the Use of 1,4-Butanediol
Deborah L. Zvosec, Ph.D., Stephen W. Smith, M.D., J. Rod McCutcheon, B.S., Joe Spillane, Pharm.D., Bradley J. Hall, Ph.D., and Elizabeth A. Peacock, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background 1,4-Butanediol is an industrial solvent that, when ingested, is converted to {gamma}-hydroxybutyrate, a drug of abuse with depressant effects, primarily on the central nervous system. After reports of toxic effects of {gamma}-hydroxybutyrate and its resultant regulation by the federal government, 1,4-butanediol and {gamma}-butyrolactone, another precursor of {gamma}-hydroxybutyrate and an industrial solvent, began to be marketed as dietary supplements. We investigated reports of toxic effects due to the ingestion of 1,4-butanediol and reviewed the related health risks.

Methods From June 1999 through December 1999, we identified cases of toxic effects of 1,4-butanediol involving patients who presented to our emergency departments with a clinical syndrome suggesting toxic effects of {gamma}-hydroxybutyrate and a history of ingesting 1,4-butanediol and patients identified through public health officials and family members. We used gas chromatography–mass spectrometry to measure 1,4-butanediol or its metabolite, {gamma}-hydroxybutyrate, in urine, serum, or blood.

Results We identified nine episodes of toxic effects in eight patients who had ingested 1,4-butanediol recreationally, to enhance bodybuilding, or to treat depression or insomnia. One patient presented twice with toxic effects and had withdrawal symptoms after her second presentation. Clinical findings and adverse events included vomiting, urinary and fecal incontinence, agitation, combativeness, a labile level of consciousness, respiratory depression, and death. No additional intoxicants were identified in six patients, including the two who died. The doses of 1,4-butanediol ingested ranged from 5.4 to 20 g in the patients who died and ranged from 1 to 14 g in the nonfatal cases. In some cases there was evidence of addiction and withdrawal.

Conclusions The health risks of 1,4-butanediol are similar to those of its counterparts, {gamma}-hydroxybutyrate and {gamma}-butyrolactone. These include acute toxic effects, which may be fatal, and addiction and withdrawal.


Source Information

From the Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis (D.L.Z., S.W.S.); the Office of the Travis County Medical Examiner, Austin, Tex. (J.R.M., B.J.H., E.A.P.); and Broward General Medical Center, Nova Southeastern University, Fort Lauderdale, Fla. (J.S.).

Address reprint requests to Dr. Smith at the Department of Emergency Medicine, Hennepin County Medical Center, 701 Park Ave., Minneapolis, MN 55415-1829, or to Dr. Zvosec at dzvosec{at}hotmail.com.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.